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Abstract 
Background: Monitoring the impact of case management strategies at large scale is essential to evaluate the public 
health benefit they confer. The use of methodologies relying on objective and standardized endpoints, such as drug 
levels in the blood, should be encouraged. Population drug use, diagnosis and treatment appropriateness in case of 
fever according to patient history and anti-malarials blood concentration was evaluated.
Methods: A cross-sectional survey took place between May and August 2015 in three regions of Tanzania with differ-
ent levels of malaria endemicity. Interviews were conducted and blood samples were collected by dried blood spots 
through household surveys for further anti-malarial measurements. Appropriate testing when individuals attended 
care was defined as a patient with history of fever being tested for malaria and appropriate treatment as (i) having 
anti-malarial in the blood if the test result was positive (ii) having anti-malarial in the blood if the person was not 
tested, and (iii) no anti-malarial in the blood when the test result was negative.
Results: Amongst 6391 participants included in the anti-malarial analysis, 20.8% (1330/6391) had anti-malarial drug 
detected in the blood. Only 28.0% (372/1330) of the individuals with anti-malarials in their blood reported the use of 
anti-malarials within the previous month. Amongst all participants, 16.0% (1021/6391) reported having had a fever in the 
previous 2 weeks and 37.5% of them (383/1021) had detectable levels of anti-malarials in the blood. Of the individuals who 
sought care in health facilities, 69.4% (172/248) were tested and 52.0% (129/248) appropriately treated. When other provid-
ers were sought, 6% (23/382) of the persons were appropriately tested and 44.2% (169/382) appropriately treated. Overall, 
the proportion of individuals treated was larger than that being tested [47.3% (298/630) treated, 31.0% (195/630) tested].
Conclusion: This study showed high prevalence of circulating anti-malarial drug in the sampled population. Efforts 
should be made to increase rapid diagnostic tests use at all levels of health care and improve compliance to test result 
in order to target febrile patients that are sick with malaria and reduce drug pressure. Objective drug measurements 
collected at community level represent a reliable tool to evaluate overall impact of case management strategies on 
population drug pressure.
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Background
The implementation of artemisinin-based combination 
therapy (ACT) and malaria rapid diagnostic tests (RDTs) 
has been a cornerstone in the management of fever 
cases. These tools are essential components of the cur-
rent global malaria control strategy [1–3]. In Tanzania, a 
good coverage of preventive and curative interventions, 
including the distribution of insecticide-treated nets 
and the adoption of ACT as first-line therapy, has led to 
a decrease in the number of malaria cases of more than 
75% between 2000 and 2015 [4]. Considerable efforts 
have been made to expand access to effective anti-malar-
ials in the public and private sector. In 2014, Tanzania 
has reported that sufficient ACT medicines had been dis-
tributed across the country to treat all patients attending 
public health facilities [5]. Malaria RDTs have also been 
deployed to reach half of the population so far, and health 
workers have been trained in using them [4, 6]. Recent 
surveys have reported that availability of malaria testing 
was 83% in the public sector where more than 70% of the 
suspected cases were tested [4, 7]. This was not the case 
in the private sector where there was only 16% of test-
ing available [7]. Diagnosis availability and compliance to 
diagnosis results are major factors to reach rational use 
of treatments. Although the Tanzania National Malaria 
Control Programme (NMCP) case management poli-
cies, recommended by the World Health Organization 
(WHO) requires parasitological confirmation of malaria 
prior to treatment for patients of all ages, there are con-
cerns that many patients with malaria do not receive 
ACT while others suffering from non-malarial fever do. 
This indicates that treatments are not always targeted to 
those in need [2, 3, 6]. While under-treatment needs to 
be addressed with improved access to drugs, over-treat-
ment due to non-availability of malaria tests or lack of 
expertise of clinicians in the management of non-malaria 
fevers has becomes a concern increasingly important, 
especially with global decrease in proportion of febrile ill-
nesses due to malaria [8, 9]. Incorrect malaria prescrip-
tions result in wastage of medication, delays in obtaining 
effective treatment for the true cause of illness, important 
drug pressure in the population [10] and hence emer-
gence of parasite resistance to drugs [11].
Monitoring case management strategies and evaluating 
their impact are important activities to ensure that they 
confer the foreseen individual and public health benefit 
they are supposed to. To that end, interviews targeting 
caretakers of small children in community based cross-
sectional surveys as well as data collection in health 
facilities or in the retail sector have been used to estimate 
levels of access to good quality drugs and the impact of 
RDTs use on drug prescription [5, 6, 12–14]. These stud-
ies inherently suffer from potential biases, such as recall 
bias and inaccurate reporting due to fear to be judged or 
fear of not being appropriately cared for [15]. They are 
also more likely to detect a positive effect since they are 
usually conducted in places where intense training and 
supervision have been undertaken, or are biased due 
to the Hawthorne effect [16]. Two studies conducted in 
Tanzania and in Cambodia showed that self-reported 
history is not reliable in terms of actual drug use. Indeed, 
75% of patients presenting in a health facility in Tanza-
nia and 50% in Cambodia had detectable concentrations 
of anti-malarials in the blood, although all stated that 
they did not take any drug in the previous month [17, 
18]. Besides recourse to public health facilities, febrile 
patients often seek care in the private sector, and espe-
cially so among drug retailers that are usually prohibited 
to sell and perform RDT testing which is the case in Tan-
zania, except for registered accredited drug dispensing 
outlets (ADDOs) [5, 9, 10, 19, 20]. As a result, a consid-
erable amount of patients are prescribed anti-malarial 
treatments presumptively. For all these reasons, the 
overall impact of the implementation of RDTs and ACT 
is difficult to assess precisely. There is a need to apply 
more rigorous and reliable methodologies to evaluate the 
appropriateness of case management for fever episodes 
at large scale. The aim of this study was to use anti-malar-
ials blood levels as an objective and standardized end-
point to evaluate population drug use, to compare these 
results with self-reported history, and to assess diagnosis 
and treatment appropriateness in case of fever episode at 
population level.
Methods
Study design
This cross-sectional survey included three types of sur-
veys conducted concurrently in randomly selected wards 
(which is the smallest administrative area and includes 
five to seven villages): (1) household-based surveys, 
(2) drug outlet-based surveys and (3) exit interviews in 
health facility-based surveys.
Study areas and population
The surveys took place in 2015, after the rainy season in 
three regions of Tanzania: Mtwara, Mwanza and Mbeya 
with populations of 1 270 854, 2 772 509 and 2 707 410, 
respectively [21]. The IMPACT2 project [5], whose 
main objective was to assess the impact of the Afford-
able Medicines Facility-malaria (AMFm) initiative on 
the supply and demand of ACT medicines, served as a 
basis for the choice of the regions in this study. In this 
study performed in 2012, the level of malaria prevalence 
amongst all age groups was moderately high for Mtwara 
and Mwanza (17.4 and 16.1% respectively), and low for 
Mbeya (2.3%). Tanzania is an area of year-round malaria 
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transmission, with a bimodal pattern, peaking after the 
rainy season. Each region includes urban and rural dis-
tricts, although the populations are predominantly rural. 
Tanzania has four different administrative levels, the 
highest level being the region. Regions are divided into 
districts and these are sub-divided into divisions and 
further into wards. Fever case management in the pub-
lic sector is provided by a network of regional and dis-
trict hospitals as well as health centres and dispensaries 
at lower administrative levels [22]. The private sector 
includes for profit and not-for-profit facilities (hospital 
and clinics) and a drug outlets network which is mainly 
constituted of regulated and non-regulated drug shops, 
while registered pharmacies are almost exclusively 
located in major urban areas [23, 24].
Study sampling
One urban and two rural districts were selected in each 
study region. Three wards were randomly selected pro-
portionally to their population size in each district. In 
each urban ward, four streets and in each rural ward, two 
villages as well as two sub villages in each village were 
randomly selected. After obtaining the list of the house-
holds within each sub village/street, 20 households were 
randomly sampled for the household surveys. In each 
sampled household, up to six participants were randomly 
selected from the complete list of the household mem-
bers until a total of 60 individuals per sub-village/street 
was reached, resulting in 240 individuals sampled per 
ward. All consenting individuals were eligible to partici-
pate. The exclusion criteria were individuals with a severe 
illness requiring immediate referral and those under 
3 months of age.
Data collection procedures
Household surveys
Interviews were conducted with a questionnaire in Swa-
hili, first with the head of household. The questions also 
included information on time to the closest health facil-
ity and closest pharmacy or drug retailers. Randomly 
selected members were then asked about demographic 
information, history of fever in the previous 2  weeks 
as well as history of anti-malarial use in the previous 
months. Members who reported fever in the previous 
2  weeks were asked about treatment-seeking behav-
iour including place where they sought care, informa-
tion on malaria diagnosis testing and drugs received and 
ingested. Data was collected using electronic tablets with 
the help of the Open Data Kit collection tool (ODK). 
Each visited household was mapped using Global Posi-
tioning System. In addition, blood spots were collected 
from finger prick onto filter paper to assess the presence 
of malaria antigens and for further drug concentrations 
measurements.
Outlet surveys
Drug-outlet surveys were conducted in all private and 
public outlets surrounding and serving the selected vil-
lages/streets. These included small district hospitals, 
public and private health centres, dispensaries, pharma-
cies, registered ADDOs and non-registered drug retail-
ers, general stores and kiosks. Following verbal consent 
of the most senior staff present at the moment of the 
survey, details about anti-malarials stocks and diagnostic 
tools (RDTs and microscope) available at the time of the 
visit were recorded.
Exit interviews of patients in health facilities
In each ward, the main health facilities (which included 
district hospitals, health centres and/or dispensaries) 
serving the surveyed villages were selected for the exit 
interviews. After completion of their consultation with 
health facility staff and after visiting the health facility 
pharmacy for possible treatment procurement, patients 
were interviewed and information were collected on 
demographics, administration of malaria diagnostic test-
ing (microscopy or RDTs), test result and drug obten-
tion. In addition, RDT was performed on site by the field 
investigators.
Laboratory procedures
Capillary blood samples were taken by fingerprick on all 
subjects interviewed during the household surveys. One 
drop of blood was immediately used for RDTs analysis 
(ParaHIT-f test, Span diagnostic Ltd, Surat, India, detect-
ing HRP-2 antigens) and four drops were applied on filter 
paper cards (FTA DMPK-B cards, Whatman, GE Health-
care). These were able to dry at room temperature for at 
least two hours before being placed in a specific bag with 
desiccant and stored in a − 10  °C freezer at the end of 
the day and finally transferred to a − 80 °C freezer within 
1 month. Concentrations of seven anti-malarials and two 
metabolites, namely amodiaquine, N-desethyl-amodi-
aquine, lumefantrine, desbutyl-lumefantrine, mefloquine, 
chloroquine, quinine, sulfadoxine and pyrimethamine, 
were determined in the dried blood spots (DBS) sam-
ples by liquid chromatography coupled to tandem mass 
spectrometry (LC–MS/MS) [25, 26]. The LC–MS/MS 
platform enables to detect residual blood levels if the 
drug was taken up to 4 weeks prior to the analysis (given 
the long half-lives of the measured anti-malarials). Due 
the very short half-life of artemisinin compounds, and 
because they are rapidly degraded due to haemolysis with 
the current collection procedure, their analysis were not 
performed in these DBS samples.
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Definitions
Fever was defined as any illness with fever reported in 
the 2  weeks prior to the survey. Malaria infection was 
defined as a positive RDT result on the day of the survey. 
Anti-malarials identified during the outlet surveys were 
classified according to their active ingredients and drug 
formulation. For data analysis, outlets were considered to 
have RDTs and anti-malarials in stock if the study team 
observed at least one non-expired test or at least one 
complete non-expired treatment of any anti-malarial for 
any age/weight group. Individuals were considered hav-
ing anti-malarials in the blood if at least one of the nine 
anti-malarials/metabolites were measured in their corre-
sponding DBS sample, at a concentration equal or higher 
than the lower limit of quantification. The latter is the 
minimal concentration that confidently provides a bias 
and coefficient of variation within ± 20% [27]. For this 
analysis, dispensaries, public, private or mission health 
centres and small district hospitals were classified as 
“health facilities”. Pharmacies, registered (ADDOs) and 
non-registered drug retailers, general stores and kiosks 
were grouped as “non-health facility anti-malarial pro-
viders”. Traditional practitioner, neighbours, friends or 
even home (if medication available) were classified as 
“other places”. Appropriate diagnosis was defined as a 
patient with history of fever being tested for malaria (by 
RDT or microscopy) and appropriate treatment as having 
anti-malarial in the blood or not in agreement with RDT 
result. Treatment was also considered as being appro-
priate if a febrile individual was not tested and had anti-
malarials detected in the blood, as per WHO guidelines 
when diagnostic testing is not possible [3].
Data management and statistical analysis
Data was stored on the ODK Aggregate data repository 
at the end of each survey day. During each interview, 
key data such as demographic information and RDT 
results were also collected on paper forms. These data 
were cross-checked twice with electronic data at the end 
of each day. R (version 3.4.0) was used for data cleaning 
and management and to produce summary statistics as 
well as graphics using the ggplot2 package. p values were 
calculated using Pearson Χ2 statistics with significance 
defined as p < 0.05.
Results
The household survey included a total of 6485 partici-
pants. On average, 120 individuals were interviewed 
in each village. The outlet survey included 2 hospitals, 
19 health centres, 39 dispensaries, 78 ADDOs, 57 drug 
stores, 9 pharmacies and 4 general stores or kiosks.
Population characteristics in the household surveys
In the household survey, 4503/6485 (69.4%) participants 
were sampled in the two regions with moderately high 
malaria endemicity [2141/6485 (33.0%) in Mtwara and 
2362/6485 (36.4%) in Mwanza] and 1982/6485 (30.6%) 
in the region with low endemicity (Mbeya) (Table  1). 
The majority of the participants lived in rural districts 
(4280/6485, 66.0%). The sample included 3623 (55.9%) 
females with a median age of 20  years (age range from 
3  months to 95  years) and 2846 (43.9%) males with a 
median age of 14  years (age range from 3  months to 
100 years). On the day of the survey, 1039/6485 (16.0%) 
participants reported a history of fever in the last 2 weeks 
prior the survey and 1136/6485 (17.5%) were tested posi-
tive for malaria by RDT.
Prevalence of Plasmodium falciparum and anti‑malarials 
in the blood of the surveyed population
Out of the 6485 participants, 94 were excluded from 
the anti-malarial analysis because their blood samples 
were not found or were mislabelled. Thus, 6391 partici-
pants remained with a valid anti-malarial measurement. 
Mtwara was the region with the highest malaria preva-
lence [25.9%, 95% confidence interval (CI) 24.4–27.5], fol-
lowed by Mwanza (21.2%, 95% CI 19.8–22.6) and Mbeya 
(4.1%, 95% CI 3.4–4.9). The presence of anti-malarials 
was detected in the blood of 20.8% (95% CI 20.0–21.6, 
1330/6391) of individuals in total. The proportion of indi-
viduals with residual levels of anti-malarials in the blood 
was 19.3% (95% CI 17.9–20.7) in Mtwara, 28.0% (95% CI 
26.4–29.5) in Mwanza and 14.1% (95% CI 12.8–15.3) in 
Mbeya (Fig. 1).
Reliability of medical history
Out of the 1330 individuals with anti-malarials in their 
blood, only 28.0% (372/1330) reported the use of anti-
malarials within the previous month, irrespective of fever 
status in the previous 2 weeks, as represented in Fig. 2a. 
There was only a 21.0% (372/1768) overlap between the 
individuals reporting anti-malarial use and those having 
detectable concentrations of anti-malarials in their blood.
Amongst the 6391 participants with a valid anti-
malarial measurement, 16.0% (1021/6391) reported hav-
ing had a fever in the previous 2  weeks. About 37.5% 
(383/1021) of them had detectable levels of anti-malarials 
in the blood (Fig. 2b). The overlap between the individu-
als reporting a fever and those having detectable con-
centrations of anti-malarials in their blood was 19.5% 
(383/1968). Participants who did not report any fever in 
the previous 2  weeks accounted for the majority of the 
individuals who had residual anti-malarial levels detected 
in their blood [71.2% (947/1330)].
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Seeking‑care behaviour in case of fever
Figure  3 presents the proportion of febrile individuals 
who sought care and those amongst them who had anti-
malarials in their blood, according to the type of care 
providers they visited. Amongst the 37.5% (383/1021) 
of febrile individuals who had anti-malarials in the 
blood, the proportion who sought care in health facili-
ties was lower than in non-health facility anti-malarial 
providers [11.3% (115/1021) vs. 16.6% (170/1021)]. 
8.3% (84/1021) said they did not seek care and 1.3% 
(13/1021) reported seeking care by a friend or by a tra-
ditional healer or took a drug from their home.
Table 1 Population characteristics of participants in household surveys and febrile outpatients exiting health facilities
a Based on self-report, b Not applicable
Participants in household surveys (N = 6485) Febrile outpatients, health facility exit interviews 
(N = 226)
N % 95% CI N % 95% CI
Total 6485 100.0 – 226 100.0 –
Sex
 Male 2846 43.9 (42.9–45.0) 99 43.8 (38.4–49.2)
 Female 3623 55.9 (55.0–57.0) 127 56.2 (50.8–61.6)
 Missing 16 0.2 – 0 0.0 –
Age (years)
 0–4 1153 17.8 (17.0–18.6) 148 65.5 (60.3–70.7)
 5–9 1014 15.6 (14.8–16.3) 48 21.2 (16.8–25.7)
 10–14 775 11.9 (11.3–12.6) 9 4.0 (1.8–6.1)
 15–24 990 15.3 (14.6–16.1) 6 2.7 (0.9–4.4)
 25–44 1437 22.2 (21.4–23.1) 10 4.4 (2.2–6.7)
 45–59 559 8.6 (8.1–9.2) 3 1.3 (0.1–2.6)
 60–100 454 7.0 (6.5–7.65) 2 0.9 (− 0.1 to 1.9)
 Missing 103 1.6 – 0 0.0 –
Area
 Urban 2205 34.0 (33.0–35.0) 50 22.1 (17.6–26.7)
 Rural 4280 66.0 (65.0–67.0) 176 77.9 (73.3–82.4)
 Missing 0 0.0 0 0.0
Region
 Mwanza 2362 36.4 (35.4–37.4) 45 19.9 (15.5–24.3)
 Mbeya 1982 30.6 (29.6–31.5) 37 16.4 (12.3–20.4)
 Mtwara 2141 33.0 (32.1–34.0) 144 63.7 (58.5–69.0)
 Missing 0 0.0 – 0 0.0 –
Had a fever in the previous 2 weeksa
 Yes 1039 16.0 (15.3–16.8) 100 – –
 No 5440 83.9 (83.1–84.6) 0 – –
 Don’t know 6 0.1 – 0 – –
RDT result
 Positive 1136 17.5 (16.7–18.3) 106 46.9 (41.4–52.4)
 Negative 5346 82.5 (81.7–83.3) 119 52.7 (47.2–58.2)
 Missing 3 0.0 – 1 0.4 –
Took any anti-malarial drugs in the previous 4 weeksa
 Yes 810 12.5 (11.8–13.2) NAb
 No 5664 87.3 (86.7–88.0) NA
 Don’t know 11 0.2 – NA
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Appropriateness of malaria diagnosis (according 
to medical history) and treatment (based on anti‑malarials 
in the blood) in health facilities and non‑health facility 
anti‑malarial providers
As shown in Fig. 4, proportion of participants with fever 
who reported they had been tested for malaria at the 
place they sought care was 31.0% (195/630), with a large 
statistically significant difference between health facili-
ties and non-health facility anti-malarial providers [69.4% 
(172/248) vs. 6.0% (23/382), respectively; p < 0.001)]. 
The overall proportion of people being appropriately 
treated was 47.3% (298/630). This proportion was 52.0% 
(129/248) in health facilities vs 44.2% (169/382) for non-
health facility anti-malarial providers (p = 0.04). Only 
half of the individuals who were tested positive by RDT 
in the health facilities had anti-malarials detected in their 
blood [52.9% (74/140)]. This was close to those who were 
not tested [45.2% (33/73) in health facilities and 42.9% 
(154/359) in non-health facility anti-malarial providers]. 
One-third of the individuals tested negative in the health 
facilities had detectable levels of anti-malarials in their 
blood [26.7% (8/30)]. Overall, the proportion of indi-
viduals treated was larger than that being tested [45.2% 
(285/630) treated, 31.0% (195/630) tested].
Appropriateness of malaria treatments assessed 
by medical history and anti‑malarials in the blood 
in household surveys
When assessed based on participant’s medical history 
recorded in household surveys, the proportion of indi-
viduals who mentioned being appropriately treated 
according to diagnostic test result or who stated being 
treated presumptively was significantly higher than when 
it was assessed on the basis of presence or absence of 
anti-malarials in the blood, as shown in Fig. 5 (65.3% vs. 
19.3%
25.9%
0
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Fig. 1 Proportions of individuals with residual anti-malarials in their blood and individuals with Plasmodium falciparum. The presence of 
anti-malarials in the blood was measured using dried blood spots samples and parasite prevalence using RDTs. These proportions were obtained 
from household surveys in three regions of Tanzania
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52.0%, p < 0.01 in health facilities and 66.0% vs. 44.3%, 
p < 0.001 for non-health facility anti-malarial providers).
Availability of anti‑malarial treatments and RDTs in each 
region
Mbeya was the only region in which all health care 
providers (health facilities and non-health facility 
anti-malarial providers) had anti-malarials in stock 
(Table  2). The availability of malaria blood testing (by 
RDT or microscopy) was the highest in Mbeya in all 
types of care providers (88.9% in health facilities and 
7.9% in non-health facility anti-malarial providers). 
68.8% of the health facilities in Mtwara and 80.8% in 
Mwanza had malaria diagnosis tools available. Very few 
non-health facility anti-malarial providers had RDTs in 
stock in these two regions (0.0% in Mtwara and 1.1% in 
Mwanza). In both types of care providers and in each 
region, the commodities to treat were higher than the 
potential to test for malaria.
Exit interviews
A total of 456 outpatients were interviewed in 37 
nearby health facilities (3 hospitals, 17 health centres 
and 17 dispensaries), but for the present analysis, only 
the 226 febrile patients were considered (Table 1). The 
proportion of interviewees that reported they had been 
tested at the health facility was 65.9% (149/226), a pro-
portion that is close to that obtained through house-
hold surveys [69.4% (172/248)]. 65.0% (147/226) had 
received appropriate treatment, a proportion that is 
higher than that in household surveys, although this 
difference was not statistically significant (p = 0.16). 
During the interviews, 46.9% (106/226) febrile partici-
pants were tested positive by RDT by the field investi-
gators, a proportion which is lower than that reported 
through household surveys [81.4% (140/172), p < 0.01].
Discussion
According to relevant literature, this is the first study 
investigating the presence of anti-malarials in the blood 
of the general population. The measurement of nine 
anti-malarials provided a reliable endpoint and allowed 
a comprehensive assessment of drug use and current 
malaria case management landscape in the studied 
communities.
This study showed that close to one-fifth (20.8%) of 
individuals in the community had residual anti-malari-
als in their blood, even in Mbeya, a region of low ende-
micity of malaria. The absence of relationship between 
the level of transmission and the drug-prescribing 
behaviour has also been observed in another study in 
Tanzania [28]. The high prevalence of individuals with 
anti-malarials in the blood in Mwanza and Mbeya in 
comparison to the prevalence of Plasmodium falcipa-
rum does not seem to be related to low testing avail-
able since these two regions had higher proportions of 
health care facilities with malaria diagnostic tools in 
stock. However, having diagnostic tools available does 
not guarantee their usage, or that clinicians are compli-
ant to tests results. The testing habits might be lower 
in these two regions, and especially so in Mbeya where 
the probability of a fever being malaria is much lower 
than in Mwanza or Mtwara because of the higher alti-
tude [22].
More access to drugs might be one explanation. Indeed 
the study team was able to visit 115 nearby outlets in 
Mwanza, 56 in Mbeya, but only 37 in Mtwara for roughly 
the same number of individuals in the vicinity. Mwanza 
was the region with the highest proportion of individu-
als with anti-malarials in the blood, and also the high-
est prevalence of fever (34.0% in Mwanza vs. 14.6% in 
Mtwara and 9.3% in Mbeya). More febrile episodes in 
Mwanza could be due to a higher prevalence of other 
causes of fever (e.g. arboviruses) which might be wrongly 
allocated to malaria [29]. Alternatively, the population 
1968 individuals
said they had a fever (history +) or had antimalarials in the blood (blood +) 
32%
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history + / blood -
20%
(383/1968)
history + / blood + 
48%
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history - / blood + 
b
1768 individuals
said they used antimalarials (history +) or had antimalarials in the blood (blood +) 
25%
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a
Fig. 2 Overlap between self-reported history of anti-malarial use 
(a) or fever (b) and anti-malarials in the blood. Overlap between: (a) 
individuals reporting anti-malarial use in the previous month or (b) 
individuals reporting fever in the previous 2 weeks, and individuals 
with detectable concentrations of anti-malarial drugs in their blood 
(dried blood spots samples) in the household surveys
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of Mwanza might have a lower level of malaria immu-
nity than that of Mtwara, with a proportion of Plasmo-
dium infections that progress to clinical manifestations 
being higher in this setting of lower endemicity, and 
hence higher prevalence of individuals treated with anti-
malarials [30]. The study results confirm this hypothesis 
with 35% of the individuals tested positive for malaria 
in Mwanza reporting having had a fever in the previous 
2 weeks, against only 23% in Mtwara.
Whatever the reasons are for the high prevalence of 
people with anti-malarials in the blood, access to drugs 
does not seem to be a major issue in these communi-
ties, but rather appropriate case management to target 
those febrile patients that are sick with malaria. The 
important drug pressure across these three regions is 
worrying because the occurrence of a low drug level 
in blood induces strong selective pressure on parasites 
and causes the emergence of drug resistance [11, 31].
When using an objective endpoint such as the con-
centration of anti-malarials in the blood, it appears that 
self-reporting of drug intake is unreliable, with only 
28% concordance for individuals having detectable lev-
els of anti-malarials in their blood reporting the use of 
such treatments within the previous month, and 54% 
pretending having taken any drug actually having no 
residual anti-malarials in their blood. Poor agreement 
between history taking and anti-malarial concentration 
measurement has already been shown in two previous 
small-scale studies that were conducted among Tanza-
nian and Cambodian patients attending a health facility 
[17, 18], and in a cross-sectional survey in Uganda [32].
Amongst the individuals who had detectable levels of 
anti-malarials in their blood, 71% said they did not have 
fever in the previous 2 weeks and 6% said they had fever 
but did not seek care. Again, these results show that his-
tory taking is very unreliable and that all previous stud-
ies that described health seeking behaviour and drug 
consumption [12, 13, 33] should be taken with caution, 
as they leave aside a considerable part of the population 
using drugs. Although it has been shown that history 
validity can be improved [34], new technology platforms 
such as LC–MS/MS performed on DBS samples allow 
to move from subjective to objective and reproducible 
data. There is obviously a question of feasibility (ideally 
the DBS should be stored frozen) and cost (50 dollars for 
measurement of nine different anti-malarials by LC–MS/
MS in one DBS sample) to conduct large-scale surveys, 
but certainly such objective assessment could be used as 
a validation method for other more practical tools.
Another main finding of this study is the poor diag-
nosis and treatment practices in case of febrile episode. 
Overall, only one-third of the febrile individuals being 
0
40
80
P
ro
po
rti
on
 (%
)
HEALTH 
FACILITIES
OTHER 
ANTIMALARIAL 
PROVIDERS
OTHER PLACES DID NOT 
SEEK CARE
24.3%
37.4%
3.2%
35.1%
11.3%
16.6%
1.3%
8.3%
GOVERNMENT HEALTH FACILITIES
PRIVATE HEALTH FACILITIES
DRUG STORES
GENERAL STORES AND KIOSKS
ADDOS
COMMUNITY HEALTH WORKER
PHARMACIES
HOME
TRADITIONAL HEALERS
STREET DOCTORS
OTHER PLACES
DID NOT SEEK CARE
HAD ANTIMALARIALS IN THE BLOOD
Fig. 3 Prevalence of individuals with anti-malarials in their blood according to health-seeking behaviour. The top of the chart is based on the 
self-reported history of health-seeking behaviour of individuals who had a febrile episode in the previous 2 weeks. The bottom of the chart presents 
the corresponding prevalence of individuals with anti-malarial drug in their blood
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tested for malaria at the place they sought care and about 
half being appropriately treated according to their diag-
nostic test result, or presumptively if no diagnostic tool 
was available. Presumptive treatment is thus still com-
mon, and far from the goal set by the WHO of systematic 
testing of suspected malaria cases and treatment upon 
result [3]. The low testing rate is mainly due to the high 
proportion of individuals seeking care outside the health 
facilities where patients are usually not tested. Allow-
ing drug retailers to perform malaria testing might be 
one way of reducing the numbers of anti-malarials sells 
and consumption. In Tanzania, an ongoing research in 
which dispensers from ADDOs in intervention districts 
are trained to perform RDTs and treating with first-line 
treatment has already shown encouraging results with an 
increase from 0 to 65% of suspected malaria patients vis-
iting a shop being tested [10].
The proportion of febrile individuals appropriately 
tested for malaria was much higher in health facilities 
than in non-health facility anti-malarial providers (70% 
vs. 6.0%), but this difference was not much reflected in a 
better targeting of treatment to individuals with malaria. 
Indeed, the proportion of patients appropriately treated 
was only eight percentage point higher in health facili-
ties than in non-health facility anti-malarial providers 
[52.0% (129/248) vs. 44.2% (169/382), p = 0.04]. This can 
be partly explained by the fact that, according to anti-
malarial drugs detected in the blood of the interviewees, 
only half of the patients tested positive were treated. The 
same proportion of anti-malarial drugs was detected in 
the blood of patients who were not tested.
In the literature, a decrease by up to three-quarters in 
ACT prescription has been observed after RDTs imple-
mentation, between 2006 and 2008 [35, 36]. A recent 
systematic review including 14 studies showed that the 
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Fig. 4 Proportion of febrile individuals appropriately diagnosed and treated for malaria. Appropriate diagnosis was defined as a patient with 
history of fever being tested for malaria (by RDT or microscopy) and appropriate treatment as having anti-malarials in the blood if the RDT result 
was positive or if the person had not been tested. The left side of the figure reports individuals who sought care in health facilities and the right 
side of the figure those who sought care in non-health facility anti-malarial providers. The upper part of the organigram is built upon self-reported 
history and the bottom part on results of anti-malarials measured in blood samples collected during the household survey, which constitute more 
objective information
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overall compliance to positive and negative RDT results 
was 97 and 78%, respectively, and that lower levels of 
health care workers complied better that the more pro-
fessional counterparts [37]. The results of the present 
study are less encouraging since the fever cases were not 
always tested and appropriately treated. Studies rolled 
out in places where training has been done are more 
likely to detect a positive effect and a change observed 
at a given time point might not be sustainable. Besides, 
the study findings add to previous household surveys 
conducted in the same regions 3  years before which 
showed no significant change in the proportion of febrile 
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Fig. 5 Comparison between appropriateness of treatment assessed according to self-reported medical history and anti-malarials blood 
measurements. The proportions of febrile individuals interviewed in household surveys appropriately treated for malaria when they sought care in 
health facilities (left side of the figure) and non-health facility anti-malarial providers (right side of the figure) are assessed according to self-reported 
medical history and anti-malarials blood measurements. There is a significant difference (*p < 0.01, **p < 0.001) between the proportion of febrile 
patients appropriately treated for malaria assessed according to self-reported medical history and anti-malarials blood measurements
Table 2 Proportion of screened outlets with anti-malarials and malaria diagnosis tools available in stock
a Non-HF AM = non-health facility anti-malarial. This table reports stocks available on the day of the survey. Health facilities include hospitals, public and private 
health facilities and dispensaries. Non-health facility anti-malarial providers include pharmacies, drug stores, ADDOs and general stores. Malaria diagnosis tools 
include RDTs and microscopy
Mbeya Mtwara Mwanza
Health facilities 
(N = 18)
Non‑HF AM 
providers 
(N = 38)a
Health facilities 
(N = 16)
Non‑HF AM 
providers (N = 21)
Health facilities 
(N = 26)
Non‑HF AM 
providers (N = 89)
N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI)
% of outlets 
with anti-
malarials in 
stock
18 100.0 38 100.0 16 100.0 20 95.2 (87.6–102.9) 26 100.0 81 91.0 (86.0–96.0)
% of outlets 
with RDTs 
in stock or 
microscopy
16 88.9 (76.7–101.1) 3 7.9 (0.7–15.1) 11 68.8 (49.7–87.8) 0 0.0 21 80.8 (68.1–935.) 1 1.2 (− 0.71–2.96)
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individuals obtaining an anti-malarial at the population 
level [5, 6]. This was explained by a reduction in the use 
of health facilities. Indeed, ADDOs are now recognized 
to be the principal source of medicines in Tanzania [38].
These results call for interventions to reinforce the 
whole system for a public health impact. Health facili-
ties priorities should focus on improving systematic 
testing and treating all positive cases. As for non-health 
facility anti-malarial providers, our findings support the 
suggestions already drawn from two recent trials that 
introducing RDTs into regulated private sector settings 
can improve malaria testing and reduce over-treatment 
[10, 39]. Testing and treating should also be encouraged 
at low level of health care, e.g. at the level of community 
health workers, as it has been proven to improve well-
targeted ACT in randomized cross-over trials in Africa 
[40, 41].
In addition, care should be taken when assessing appro-
priateness of treatment in the population. This study 
observed a higher proportion of appropriate treatment 
when assessed by self-reported medical history than by 
anti-malarials measured in the blood and there are sev-
eral potential reasons to explain such discrepancies: in 
case of a positive test result, the treatment received may 
have not been an anti-malarial or patient might have 
poorly adhered to their treatments [19, 42, 43]. In the 
case of a negative result, patients could have obtained a 
treatment from the informal sector and not reporting it.
Exit interviews confirmed the findings of the house-
hold surveys. Only 58% of the patients tested positive 
by the field investigators prior leaving the health facili-
ties had received treatment against malaria during their 
consultation. The most likely scenario is poor compli-
ance by health professionals to an RDT positive result 
and no presumptive treatment prescribed to fever cases 
not tested. In contrast, a rather small proportion of the 
patients tested negative received a treatment (11%), 
which indicates a good compliance to negative results. 
Such findings imply that if more febrile patients would be 
tested, the amount of unnecessary treatment distributed 
would decrease.
The present study has several limitations. The history 
of fever recall was based on a 2-week period in order to 
be able to compare with previous surveys in the same 
areas, but residual anti-malarial drugs can eventually 
be detected in the blood for up to 4  weeks. This could 
explain why a proportion (71%) of individuals who did 
not report a fever in the previous 2  weeks had detect-
able levels of anti-malarials in the blood. However, as 
already mentioned before, history of drug intake was 
made on a 4-week period record in order to make the 
comparison between self-reported use and blood lev-
els of anti-malarials possible. When assessing reliability 
of medical history, the direct comparison of history of 
drug intake based on a 1-month recall-period and drug 
measurements is limited by Lume fantrine important 
inter-individual variability [44] and by individuals’ treat-
ment adherence rate [43]. The evaluation of diagnosis 
appropriateness from household surveys was based on 
self-reported medical history only, and thus subjected to 
report bias. This limitation is nevertheless inherent to all 
studies of this kind, except for those that rely on direct 
observation of the consultation, which are subject to the 
Hawthorne effect though. Finally, this study did measure 
diagnosis and treatment practices in different settings 
(urban or rural) and different transmission areas, but 
only at one point in time.
Conclusion
Despite recent efforts that have been made to improve 
access to diagnostic tools and to reduce anti-malarials 
overuse, there is still a considerable anti-malarial drugs 
pressure at the population level. Improving rational use 
of drugs is necessary to prevent the development of 
resistance. The present findings indicate that the goal of 
the WHO guidelines of systematic diagnostic testing and 
treatment upon result is far from being reached, and that 
anti-malarial treatments are not targeted to the individu-
als in need. As resources are invested into the develop-
ment and implementation of new diagnostic tools and 
effective treatments, it is of paramount importance to 
make sure that those tools are used to their full potential, 
and properly enforced. New health care interventions 
should not only be evaluated for their impact at the level 
of health facilities, but also at the level of the community. 
However, household surveys that collect information on 
health-seeking behaviour or practices through self-his-
tory are subject to important biases. Evaluation or moni-
toring tools that rely on objective measurements such as 
drug concentration in the blood should be favoured, if 
feasible.
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